The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma

Revised response criteria for malignant lymphoma.

Cheson, B. D., Pfistner, B., Juweid, M., Gascoyne, R., Specht, L., Horning, S., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,537 · see citing works

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines

Hallek, M. J., Cheson, B. D., Catovsky, D., Caligaris‐Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M. J., Montserrat, E., Rai, K. R., et al. (2008) · Blood · doi:10.1182/blood-2007-06-093906 · Cited by 3,782 · see citing works

Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Döhner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,686 · see citing works

International uniform response criteria for multiple myeloma

Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632 · see citing works

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445 · see citing works

Multiple Myeloma

Palumbo, A. P., & Anderson, K. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,338 · see citing works

Multiple myeloma

Raje, N. S., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,164 · see citing works

Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

Creutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137 · see citing works

Initial genome sequencing and analysis of multiple myeloma

Chapman, M. A., Lawrence, M. S., Keats, J. J., Cibulskis, K., Sougnez, C. L., Schinzel, A. C., Harview, C. L., Brunet, J.-P., Ahmann, G. J., Adli, M., et al. (2011) · Nature · doi:10.1038/nature09837 · Cited by 1,422 · see citing works

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

Baccarani, M., Cortes, J. E., Pane, F., Niederwieser, D. W., Saglio, G. N., Apperley, J. F., Cervantes, F., Deininger, M. W., Gratwohl, A. A., Guilhot, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0779 · Cited by 1,276 · see citing works

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

Siegel, D. S. D., Martin, T. G., Wang, M. L., Vij, R., Jakubowiak, A. J., Lonial, S., Trudel, S., Kukreti, V., Bahlis, N. J., Alsina, M., et al. (2012) · Blood · doi:10.1182/blood-2012-05-425934 · Cited by 656 · see citing works

Accelerated Titration Designs for Phase I Clinical Trials in Oncology

Simon, R. M., Rubinstein, L., Arbuck, S. G., Christian, M. C., Freidlin, B., & Collins, J. M. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.15.1138 · Cited by 634 · see citing works

First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

Yap, T. A., Li, Y., Patnaik, A., Fearen, I., Olmos, D., Papadopoulos, K. P., Baird, R. D., Delgado, L., Taylor, A. B., Lupinacci, L. C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5263 · Cited by 540 · see citing works

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

Richardson, P. G., Siegel, D. S., Vij, R., Hofmeister, C. C., Baz, R., Jagannath, S., Chen, C., Lonial, S., Jakubowiak, A., Bahlis, N., et al. (2014) · Blood · doi:10.1182/blood-2013-11-538835 · Cited by 381 · see citing works

Clinical Course of Patients With Relapsed Multiple Myeloma

Kumar, S. K., Therneau, T. M., Gertz, M. A., Lacy, M. Q., Dispenzieri, A., Rajkumar, S. V., Fonseca, R., Witzig, T. E., Lust, J. A., Larson, D. R., et al. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.7.867 · Cited by 365 · see citing works

Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs

Markman, B., Dienstmann, R., & Tabernero, J. M. (2010) · Oncotarget · doi:10.18632/oncotarget.188 · Cited by 353 · see citing works

Mechanism and Management of AKT Inhibitor-Induced Hyperglycemia

Crouthamel, M., Kahana, J. A., Korenchuk, S., Zhang, S., Sundaresan, G., Eberwein, D. J., Brown, K. K., & Kumar, R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1253 · Cited by 130 · see citing works

Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235

McMillin, D. W., Ooi, M. G. M., Delmore, J. E., Negri, J. M., Hayden, P. J., Mitsiades, N., Jakubı́ková, J., Maira, S.-M., Garcı́a-Echeverrı́a, C., Schlossman, R. L., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4285 · Cited by 124 · see citing works

Future Directions of Next-Generation Novel Therapies, Combination Approaches, and the Development of Personalized Medicine in Myeloma

Mitsiades, C. S., Davies, F. E., Laubach, J. P., Joshua, D., Miguel, J. F. S., Anderson, K. C., & Richardson, P. G. G. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.0760 · Cited by 83 · see citing works

Darwinian evolution and tiding clones in multiple myeloma

Bahlis, N. J. (2012) · Blood · doi:10.1182/blood-2012-06-430645 · Cited by 82 · see citing works

Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival

Steinbrunn, T., Stühmer, T., Gattenlöhner, S., Rosenwald, A., Mottok, A., Unzicker, C., Einsele, H., Chatterjee, M., & Bargou, R. C. (2010) · Blood · doi:10.1182/blood-2010-05-284422 · Cited by 81 · see citing works

An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo

Cherrin, C., Haskell, K., Howell, B., Jones, R., Leander, K. R., Robinson, R., Watkins, A., Bilodeau, M. T., HOFFMAN, J. M. J., Sanderson, P. E. J., et al. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.7.11100 · Cited by 59 · see citing works

Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study.

Burris, H. A., Siu, L. L., Infante, J. R., Wheler, J. J., Kurkjian, C. D., Opalinska, J., Smith, D. A., Antal, J. M., Gauvin, J., Gonzalez, T., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3003 · Cited by 50 · see citing works

Combined targeting of <scp>MEK</scp>/<scp>MAPK</scp> and <scp>PI</scp>3<scp>K</scp>/<scp>A</scp>kt signalling in multiple myeloma

Steinbrunn, T., Stühmer, T., Sayehli, C., Chatterjee, M., Einsele, H., & Bargou, R. C. (2012) · British Journal of Haematology · doi:10.1111/bjh.12039 · Cited by 49 · see citing works

Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma

Jain, S. S., Diefenbach, C., Zain, J. M., & O’Connor (2011) · Core evidence · doi:10.2147/ce.s13838 · Cited by 47 · see citing works

The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma

Munugalavadla, V., Mariathasan, S., Slaga, D., Du, C., Berry, L., Rosario, G. D., Yan, Y., Boe, M., Sun, L., Friedman, L. S., et al. (2013) · Oncogene · doi:10.1038/onc.2012.594 · Cited by 41 · see citing works

Novel therapeutics in multiple myeloma

Stewart, A. K. (2012) · Hematology · doi:10.1179/102453312x13336169156131 · Cited by 21 · see citing works

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W. M., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,735 · see citing works

Proteasome inhibitors in cancer therapy

Manasanch, E. E., & Orlowski, R. Z. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.206 · Cited by 1,024 · see citing works

Role of PI3K/AKT pathway in cancer: the framework of malignant behavior

Jiang, N., Dai, Q., Su, X., Fu, J., Feng, X., & Peng, J. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05435-1 · Cited by 577 · see citing works

Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors

LoRusso, P. M. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0018 · Cited by 467 · see citing works

Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)

Nițulescu, G. M., Margina, D. M., Juzenas, P., Peng, Q., Olaru, O. T., Saloustros, E. S., Fenga, C., Spandidos, D. A., Libra, M., & Tsatsakis, A. M. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3306 · Cited by 370 · see citing works

The Akt pathway in oncology therapy and beyond (Review)

Nițulescu, G. M., van de Venter, M., Nițulescu, G., Ungurianu, A., Juzenas, P., Peng, Q., Olaru, O. T., Grădinaru, D., Tsatsakis, A. M., Tsoukalas, D., et al. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4597 · Cited by 329 · see citing works

Targeting AKT for cancer therapy

Shariati, M., & Meric‐Bernstam, F. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1676726 · Cited by 295 · see citing works

AKT in cancer: new molecular insights and advances in drug development

Mundi, P. S., Sachdev, J., McCourt, C., & Kalinsky, K. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13021 · Cited by 272 · see citing works

Applications of fluorine-containing amino acids for drug design

Mei, H., Han, J., Klika, K. D., Izawa, K., Sato, T., Meanwell, N. A., & Soloshonok, V. A. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111826 · Cited by 249 · see citing works

Multiple Myeloma: Available Therapies and Causes of Drug Resistance

Pinto, V., Bergantim, R., Caires, H. R., Seca, H., Guimarães, J. E., & Vasconcelos, M. H. (2020) · Cancers · doi:10.3390/cancers12020407 · Cited by 233 · see citing works

Maximising the potential of AKT inhibitors as anti-cancer treatments

Brown, J. S., & Banerji, U. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.12.001 · Cited by 222 · see citing works

Novel agents in the treatment of multiple myeloma: a review about the future

Naymagon, L., & Abdul‐Hay, M. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0282-1 · Cited by 177 · see citing works

Phosphatidylinositol 3-kinase/Akt signaling as a key mediator of tumor cell responsiveness to radiation

Toulany, M., & Rodemann, H. P. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.07.003 · Cited by 166 · see citing works

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma

Tolcher, A. W., Patnaik, A., Papadopoulos, K. P., Rasco, D. W., Becerra, C. R., Allred, A. J., Orford, K., Aktan, G., Ferron-Brady, G., Ibrahim, N., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2615-5 · Cited by 158 · see citing works

Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis

Wang, L., Liu, W., Broussy, S., Han, B., & Fang, H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1307860 · Cited by 161 · see citing works

The emergence of drug resistance to targeted cancer therapies: Clinical evidence

Sarmento‐Ribeiro, A. B., Scorilas, A., Gonçalves, A. C., Efferth, T., & Trougakos, I. P. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100646 · Cited by 141 · see citing works

Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence

Darici, S., Alkhaldi, H., Horne, G. A., Jørgensen, H. G., Marmiroli, S., & Huang, X. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092934 · Cited by 128 · see citing works

Recent advances in the pathobiology and management of Kasabach–Merritt phenomenon

O’Rafferty, C., O’Regan, G. M., Irvine, A. D., & Smith, O. P. (2015) · British Journal of Haematology · doi:10.1111/bjh.13557 · Cited by 129 · see citing works

Akt: a key transducer in cancer

Tsai, P., Lai, Y., Manne, R., Tsai, Y.-S., Sarbassov, D. D., & Lin, H. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00860-9 · Cited by 131 · see citing works

Multiple myeloma with high-risk cytogenetics and its treatment approach

Hanamura, I. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03353-5 · Cited by 122 · see citing works

Resistance to proteasome inhibitors and other targeted therapies in myeloma

Wallington-Beddoe, C. T., Sobieraj‐Teague, M., Kuss, B. J., & Pitson, S. M. (2018) · British Journal of Haematology · doi:10.1111/bjh.15210 · Cited by 111 · see citing works

Novel therapeutic strategies for multiple myeloma

Mimura, N., Hideshima, T., & Anderson, K. C. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.04.010 · Cited by 109 · see citing works

PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise

Ramakrishnan, V. G., & Kumar, S. K. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1421760 · Cited by 89 · see citing works

Protein Tyrosine Signaling and its Potential Therapeutic Implications in Carcinogenesis

Kim, M., Baek, M., & Kim, D. J. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612823666170616082125 · Cited by 87 · see citing works

Multiple myeloma: signaling pathways and targeted therapy

Lu, Q., Yang, D., Li, H., Niu, T., & Tong, A. (2024) · Molecular biomedicine · doi:10.1186/s43556-024-00188-w · Cited by 90 · see citing works

Targeting signaling pathways in multiple myeloma: Pathogenesis and implication for treatments

Hu, J., & Hu, W.-X. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.11.020 · Cited by 84 · see citing works

Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma

Zhang, X., Lee, H. C., Shirazi, F., Baladandayuthapani, V., Lin, H. Y., Kuiatse, I., Wang, H., Jones, R. J., Berkova, Z., Singh, R., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0044-x · Cited by 84 · see citing works

Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management

Goldman, J. W., Mendenhall, M. A., & Rettinger, S. R. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0519 · Cited by 83 · see citing works

Structural and chemical insights into the covalent-allosteric inhibition of the protein kinase Akt

Uhlenbrock, N., Smith, S. P., Weisner, J., Landel, I., Lindemann, M., Le, T. A., Hardick, J., Gontla, R., Scheinpflug, R., Czodrowski, P., et al. (2019) · Chemical Science · doi:10.1039/c8sc05212c · Cited by 78 · see citing works

Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells

Gautam, P., Karhinen, L., Szwajda, A., Jha, S. K., Yadav, B., Aittokallio, T. A., & Wennerberg, K. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0517-3 · Cited by 66 · see citing works

Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer

Blagden, S. P., Hamilton, A. L., Mileshkin, L., Wong, S., Michael, A., Hall, M., Goh, J. C. H., Lisyanskaya, A. S., DeSilvio, M., Frangou, E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2277 · Cited by 65 · see citing works

Keratin 80 promotes migration and invasion of colorectal carcinoma by interacting with PRKDC via activating the AKT pathway

Li, C., Liu, X., Liu, Y., Liu, X., Wang, R., Liao, J., Wu, S., Fan, J., Peng, Z., Li, B., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1030-y · Cited by 60 · see citing works

A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors

Aghajanian, C. A., Bell‐McGuinn, K. M., Burris, H. A., Siu, L. L., Stayner, L.-A., Wheler, J. J., Hong, D. S., Kurkjian, C. D., Pant, S., Santiago-Walker, A., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0591-z · Cited by 58 · see citing works

Molecular target: pan-AKT in gastric cancer

Kang, B. W., & Chau, I. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000728 · Cited by 57 · see citing works

CNS germinomas are characterized by global demethylation, chromosomal instability and mutational activation of the Kit-, Ras/Raf/Erk- and Akt-pathways

Schulte, S., Waha, A., Steiger, B., Denkhaus, D., Dörner, E., Calaminus, G., Leuschner, I., & Pietsch, T. (2016) · Oncotarget · doi:10.18632/oncotarget.10392 · Cited by 56 · see citing works

The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies

Harding, T., Baughn, L. B., Kumar, S. K., & Ness, B. V. (2019) · Leukemia · doi:10.1038/s41375-018-0362-z · Cited by 54 · see citing works

Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment

Bolomsky, A., Schlangen, K., Schreiner, W., Zojer, N., & Ludwig, H. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0247-4 · Cited by 54 · see citing works

Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia

Puła, B., Gołoś, A., Górniak, P., & Jamroziak, K. (2019) · Cancers · doi:10.3390/cancers11121834 · Cited by 51 · see citing works

Phosphorylation-Dependent Inhibition of Akt1

Balasuriya, N., McKenna, M., Liu, X., Li, S. S. ‐., & O’Donoghue, P. (2018) · Genes · doi:10.3390/genes9090450 · Cited by 50 · see citing works

Akt Inhibitor Advancements: From Capivasertib Approval to Covalent-Allosteric Promises

Pervanidis, K. A., D’Angelo, G. D., Weisner, J., Brandherm, S., & Rauh, D. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00075 · Cited by 49 · see citing works

Crosstalk between HSPA5 arginylation and sequential ubiquitination leads to AKT degradation through autophagy flux

Kim, H. J., Kim, S., Kim, D.-H., Park, J. S., Jeong, S. H., Choi, Y. W., & Kim, C. (2020) · Autophagy · doi:10.1080/15548627.2020.1740529 · Cited by 48 · see citing works

Emerging drugs and combinations to treat multiple myeloma

Larocca, A., Mina, R., Gay, F., Bringhen, S., & Boccadoro, M. (2017) · Oncotarget · doi:10.18632/oncotarget.19269 · Cited by 44 · see citing works

Phospho-Form Specific Substrates of Protein Kinase B (AKT1)

McKenna, M., Balasuriya, N., Zhong, S., Li, S. S. ‐., & O’Donoghue, P. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.619252 · Cited by 46 · see citing works

Parkin Facilitates Proteasome Inhibitor-Induced Apoptosis via Suppression of NF-κB Activity in Hepatocellular Carcinoma

Zhang, X., Lin, C., Song, J., Chen, H., Chen, X., Ren, L., Zhou, Z., Pan, J., Yang, Z., Bao, W., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1881-x · Cited by 43 · see citing works

Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK)

Huang, X., You, L., Nepovimová, E., Psotka, M., Maliňák, D., Valko, M., Sivák, L., Korábečný, J., Heger, Z., Adam, V., et al. (2023) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2023.2237209 · Cited by 42 · see citing works

Luteolin inhibits triple-negative breast cancer by inducing apoptosis and autophagy through SGK1-FOXO3a-BNIP3 signaling

Wu, L., Lin, Y., Gao, S., Wang, Y., Pan, H., Wang, Z., Pozzolini, M., Yang, F., Zhang, H., Yang, Y. L., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1200843 · Cited by 41 · see citing works

Immune Cell Regulatory Pathways Unexplored as Host-Directed Therapeutic Targets for Mycobacterium tuberculosis : An Opportunity to Apply Precision Medicine Innovations to Infectious Diseases

Mahon, R. N., & Hafner, R. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ621 · Cited by 36 · see citing works

Pathway-Directed Therapy in Multiple Myeloma

John, L., Krauth, M. T., Podar, K., & Raab, M. (2021) · Cancers · doi:10.3390/cancers13071668 · Cited by 33 · see citing works

Medication-induced hyperglycemia and diabetes mellitus: a review of current literature and practical management strategies

Jain, A. B., & Lai, V. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01628-0 · Cited by 32 · see citing works

Targeting the PI3K/AKT signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)

Sabbah, D. A., Hajjo, R., Bardaweel, S. K., & Zhong, H. A. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2338100 · Cited by 33 · see citing works

Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors

Zhan, W., Xu, L., Dong, X., Dong, J., Yi, X., Ma, X., Qiu, N., Li, J. X., Yang, B., Zhou, Y., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.03.074 · Cited by 31 · see citing works

Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers

Shan, K. S., Bonano-Rios, A. M., Theik, N. W. Y., Hussein, A. M., & Blaya, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25041973 · Cited by 30 · see citing works

Drug targets and resistance mechanisms in multiple myeloma

Naß, J., & Efferth, T. (2018) · Cancer Drug Resistance · doi:10.20517/cdr.2018.04 · Cited by 28 · see citing works

Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies

Kumar, S. K. (2017) · Hematology · doi:10.1182/asheducation-2017.1.518 · Cited by 27 · see citing works

Cross Talk Networks of Mammalian Target of Rapamycin Signaling With the Ubiquitin Proteasome System and Their Clinical Implications in Multiple Myeloma

Eichner, R., Fernández‐Sáiz, V., Targosz, B., & Bassermann, F. C. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.06.001 · Cited by 27 · see citing works

Novel Agents in Multiple Myeloma

Szalat, R. E., & Munshi, N. C. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000355 · Cited by 27 · see citing works

A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK

Dean, E. J., Banerji, U., Schellens, J. H. M., Krebs, M., Jiménez, B., van Brummelen, E. M. J., Bailey, C., Casson, E., Cripps, D., Cullberg, M., et al. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3558-z · Cited by 26 · see citing works

OTUB2 regulates KRT80 stability via deubiquitination and promotes tumour proliferation in gastric cancer

Ouyang, S., Zeng, Z., Liu, Z., Zhang, Z., Sun, J., Wang, X., Ma, M., Ye, X., Yu, J., & Kang, W. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-00839-3 · Cited by 25 · see citing works

NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma

Yen, C., & Hsiao, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113503 · Cited by 25 · see citing works

Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma

Hirano, M., Imai, Y., Kaito, Y., Murayama, T., Sato, K., Ishida, T., Yamamoto, J., Ito, T., Futami, M., Ri, M., et al. (2021) · Journal of Experimental &amp; Clinical Cancer Research · doi:10.1186/s13046-021-01909-7 · Cited by 25 · see citing works

Emerging protein kinase inhibitors for the treatment of multiple myeloma

Lind, J., Czernilofsky, F., Vallet, S., & Podar, K. (2019) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2019.1647165 · Cited by 24 · see citing works

A phase IIa study of afuresertib, an oral pan‐AKT inhibitor, in patients with Langerhans cell histiocytosis

Arceci, R. J., Allen, C. E., Dunkel, I. J., Jacobsen, E. D., Whitlock, J. A., Vassallo, R., Morris, S. R., Portnoy, A., Reedy, B. A., Smith, D. A., et al. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26325 · Cited by 24 · see citing works

Kinase inhibitors as potential agents in the treatment of multiple myeloma

Abramson, H. N. (2016) · Oncotarget · doi:10.18632/oncotarget.10745 · Cited by 23 · see citing works

Recent Advance of Akt Inhibitors in Clinical Trials

Guo, K., Tang, W., Zhuo, H., & Zhao, G. (2019) · ChemistrySelect · doi:10.1002/slct.201901293 · Cited by 23 · see citing works

Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191

Ni, H., Shirazi, F., Baladandayuthapani, V., Lin, H. Y., Kuiatse, I., Wang, H., Jones, R. J., Berkova, Z., Hitoshi, Y., Ansell, S. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3265 · Cited by 22 · see citing works

Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation

Okabe, S., Tanaka, Y., Tauchi, T., & Ohyashiki, K. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3547-7 · Cited by 21 · see citing works

Cbl-b Is Upregulated and Plays a Negative Role in Activated Human NK Cells

Lu, T., Chen, L., Mansour, A. G., Yu, M., Brooks, N., Teng, K., Li, Z., Zhang, J., Barr, T., Yu, J., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2000177 · Cited by 20 · see citing works

Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities

Zhang, J., Park, D., Shin, D. M., & Deng, X. (2015) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv118 · Cited by 19 · see citing works

Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma

Brünnert, D., Kraus, M., Stühmer, T., Kirner, S., Heiden, R., Goyal, P., Driessen, C., Bargou, R. C., & Chatterjee, M. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.04.003 · Cited by 19 · see citing works

Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS

Müller, E., Bauer, S., Stühmer, T., Mottok, A., Scholz, C. J., Steinbrunn, T., Brünnert, D., Brandl, A., Schraud, H., Kressmann, S., et al. (2016) · Leukemia · doi:10.1038/leu.2016.264 · Cited by 17 · see citing works

Novel investigational drugs active as single agents in multiple myeloma

D’Agostino, M., Salvini, M., Palumbo, A. P., Larocca, A., & Gay, F. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1324571 · Cited by 16 · see citing works

Targeting the Ras pathway in pediatric hematologic malignancies

Pikman, Y., & Stieglitz, E. (2020) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000981 · Cited by 15 · see citing works

Identification and development of a subtype-selective allosteric AKT inhibitor suitable for clinical development

Page, N., Wappett, M., O'Dowd, C. R., O’Rourke, M., Gavory, G., Zhang, L., Rountree, J. S. S., Jordan, L., Barker, O., Gibson, H., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-20208-5 · Cited by 15 · see citing works

Selectivity Studies and Free Energy Calculations of AKT Inhibitors

Zhong, H. A., & Goodwin, D. T. (2024) · Molecules · doi:10.3390/molecules29061233 · Cited by 15 · see citing works

Combining ligand- and structure-based in silico methods for the identification of natural product-based inhibitors of Akt1

Mahajan, P., Wadhwa, B., Barik, M. R., Malik, F. A., & Nargotra, A. (2019) · Molecular Diversity · doi:10.1007/s11030-019-09924-9 · Cited by 15 · see citing works

AKT1 Promotes Tumorigenesis and Metastasis by Directly Phosphorylating Hexokinases

Yu, Y., Wang, S., Wang, Y., Zhang, Q., Zhao, L., Wang, Y., Wu, J., Han, L., Wang, J., Guo, J., et al. (2024) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30613 · Cited by 14 · see citing works

Potent antitumor effect of combination therapy with sub‑optimal doses of Akt inhibitors and pomalidomide plus dexamethasone in multiple myeloma

Kinoshita, S., Ri, M., Kanamori, T., Aoki, S., Yoshida, T., Narita, T., Totani, H., Ito, A., Kusumoto, S., Ishida, T., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.8501 · Cited by 14 · see citing works

ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF‐κB in multiple myeloma

Jiang, J., Sun, Y., Xu, J., Xu, T., Zhao, X., & Liu, P. (2020) · Cancer Medicine · doi:10.1002/cam4.3347 · Cited by 12 · see citing works

Pathogenic signaling in multiple myeloma

Bolomsky, A., & Young, R. M. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.01.005 · Cited by 13 · see citing works

PDK1 inhibitor GSK2334470 synergizes with proteasome inhibitor MG‑132 in multiple myeloma cells by inhibiting full AKT activity and increasing nuclear accumulation of the PTEN protein

Zhang, J., Yang, C., Zhou, F., & Chen, X. (2018) · Oncology Reports · doi:10.3892/or.2018.6369 · Cited by 12 · see citing works

Emerging serine-threonine kinase inhibitors for treating ovarian cancer

Maoz, A., Ciccone, M. A., Matsuzaki, S., Coleman, R. L., & Matsuo, K. (2019) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2019.1696773 · Cited by 12 · see citing works

Metabolic modeling-based drug repurposing in Glioblastoma

Tomi-Andrino, C., Pandele, A., Winzer, K., King, J. R., Rahman, R., & Kim, D. (2022) · Scientific Reports · doi:10.1038/s41598-022-14721-w · Cited by 11 · see citing works

Advances in the Understanding of Akt Signaling in Cancers and the Potential of Inhibiting Akt-Driven Tumors Using Small Molecule Inhibitors: An Overview

Aswathanarayan, J. B., Naaz, R., Doreswamy, S. H., Karnik, M., Kumar, S. M. N., Sreenivasan, A., Sharma, A. K., & Madhunapantula, S. V. (2026) · Cancers · doi:10.3390/cancers18040578 · Cited by 11 · see citing works

Resibufogenin inhibits the malignant characteristics of multiple myeloma cells by blocking the PI3K/Akt signaling pathway

Zhou, Y., Hong, Z., Jin, K., Lin, C., Xiang, J., Ge, H., Zheng, Z., Shen, J., & Deng, S. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11368 · Cited by 10 · see citing works

A phase 2 study of ofatumumab (Arzerra®) in combination with a pan-AKT inhibitor (afuresertib) in previously treated patients with chronic lymphocytic leukemia (CLL)*

Chen, C. I., Paul, H. K., Le, L. W., Wei, E. N., Snitzler, S., Wang, T., Levina, O., Kakar, S., Lau, A., Queau, M. L., et al. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1468892 · Cited by 10 · see citing works

The novel AKT inhibitor afuresertib suppresses human Merkel cell carcinoma MKL‐1 cell growth

Wu, J. H., Limmer, A. L., Narayanan, D., Doan, H. Q., Simonette, R. A., Rady, P. L., & Tyring, S. K. (2021) · Clinical and Experimental Dermatology · doi:10.1111/ced.14798 · Cited by 10 · see citing works

Pathogenesis of central nervous system germ cell tumors

Liu, S. J., Ren, L., Gao, X. J., Hao, M., & Wang, G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.991484 · Cited by 10 · see citing works

Targeting Molecular Signaling Pathways and Cytokine Responses to Modulate c-MYC in Acute Myeloid Leukemia

Gu, K. J., May, H. A., & Kang, M. H. (2024) · Frontiers in Bioscience-Scholar · doi:10.31083/j.fbs1603015 · Cited by 9 · see citing works

Future Developments in the Treatment of AL Amyloidosis

Theodorakakou, F., Fotiou, D., Dimopoulos, M. A., & Kastritis, E. (2022) · Hemato · doi:10.3390/hemato3010012 · Cited by 9 · see citing works

Pancreatic Hormone Insulin Modulates Organic Anion Transporter 1 in the Kidney: Regulation via Remote Sensing and Signaling Network

Yu, Z., Zhang, J., Liang, Z., Wu, J., Liu, K., & You, G. (2023) · The AAPS Journal · doi:10.1208/s12248-022-00778-y · Cited by 9 · see citing works

Targeting Akt Signaling Pathway in Cancer: Molecular Mechanisms and Advances in Therapeutic Interventions

Leiphrakpam, P. D., Batra, R., Tenner, L. L., & Are, C. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl39100 · Cited by 9 · see citing works

SPAG5 as a novel biomarker and potential therapeutic target via regulating AKT pathway in multiple myeloma

Zeng, X., Xu, W., Tong, J., Liu, J., Zhang, Z., Liu, M., Wu, C., Yu, Q., Ye, C., Wu, C., et al. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2086247 · Cited by 8 · see citing works

Waldenström Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies

Boutilier, A. J., Huang, L., & Elsawa, S. F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911145 · Cited by 8 · see citing works

Screening of PI3K-Akt-targeting Drugs for Silkworm against Bombyx mori Nucleopolyhedrovirus

Wang, B., Jiang, L., Guo, H., Sun, Q., Wang, Y., Xie, E., & Xia, Q. (2019) · Molecules · doi:10.3390/molecules24071260 · Cited by 8 · see citing works

Gld2 activity is regulated by phosphorylation in the N-terminal domain

Chung, C. Z., Balasuriya, N., Manni, E., Liu, X., Li, S. S. ‐., O’Donoghue, P., & Heinemann, I. U. (2019) · RNA Biology · doi:10.1080/15476286.2019.1608754 · Cited by 8 · see citing works

Novel furo[2,3- d ]pyrimidine derivatives as PI3K/AKT dual inhibitors: design, synthesis, biological evaluation, and molecular dynamics simulation

Reheim, M. A. M. A., Elgammal, W. E., Bashandy, M. S., Hamed, M. I. A., AboulMagd, A. M., Khalil, M. G., Abdou, A. M., & Hassan, R. A. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00139k · Cited by 6 · see citing works

Kinase Inhibition in Multiple Myeloma: Current Scenario and Clinical Perspectives

Barreto, I. V., Machado, C. B., Almeida, D. B., Pessoa, F. M. C. D. P., Gadelha, R. B., Pantoja, L. D. C., Oliveira, D. D. S., Ribeiro, R. M., Lopes, G. S., de Moraes, M. O., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091784 · Cited by 6 · see citing works

Targeting AKT2 in MDA‐MB‐231 Cells by Pyrazole Hybrids: Structural, Biological and Molecular Docking Studies

Gaikwad, S. S., Nimal, S. K., Pol, R., Markad, D., Jadhao, A. R., Jadhav, U. U., Kate, A. N., Gacche, R. N., Patil, L. R., & Chikate, R. C. (2023) · Chemistry & Biodiversity · doi:10.1002/cbdv.202300799 · Cited by 6 · see citing works

Novel Systemic Approaches for the Management of Meningiomas

Ijad, N., Dahal, A., Kim, A. E., Wakimoto, H., Juratli, T. A., & Brastianos, P. K. (2023) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2023.02.012 · Cited by 5 · see citing works

Akt inhibitors in cancer therapy

Alam, M., Ali, S., & Hassan, M. I. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91287-7.00006-5 · Cited by 5 · see citing works

Afuresertib Shows Activity Against Multiple Myeloma

Lawrence, L. (2014)

A key to the quest?

Leleu, X. P. (2014) · Blood · doi:10.1182/blood-2014-08-593822 · Cited by 1 · see citing works

Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies

Garcia‐Manero, G., Tibes, R., Kadia, T. M., Kantarjian, H. M., Arellano, M. L., Knight, E., Xiong, H., Qin, Q., Munasinghe, W. P., Roberts-Rapp, L. A., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0242-6 · Cited by 21 · see citing works

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma

Tolcher, A. W., Patnaik, A., Papadopoulos, K. P., Rasco, D. W., Becerra, C. R., Allred, A. J., Orford, K., Aktan, G., Ferron-Brady, G., Ibrahim, N., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2615-5 · Cited by 158 · see citing works

Novel AKT Inhibitor GSK2110183 Shows Favorable Safety, Pharmacokinetics, and Clinical Activity in Multiple Myeloma. Preliminary Results From a Phase I First-Time-In-Human Study

Spencer, A. G., Yoon, S., Harrison, S. J., Morris, S. R., Smith, D. A., Freedman, S. J., Brigandi, R. A., Oliff, A. I., Opalinska, J., & Chen, C. I. (2011) · Blood · doi:10.1182/blood.v118.21.1856.1856 · Cited by 16 · see citing works